Monday, December 23, 2024
Facebook Linkedin Twitter
HomeTagsDisease-modifying therapy

disease-modifying therapy

Healthcare

U.S. Neurologists Cautiously Optimistic Following Accelerated Approval and Launch of Eisai/Biogen’s Leqembi for Early Alzheimer’s Disease, According to Spherix Global Insights

PR Newswire -
With the accelerated approval on January 6, 2023 for early Alzheimer's disease, Eisai/Biogen's Leqembi became only the second approved disease-modifying therapy (DMT) for early Alzheimer's...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us